Screening for liver disease - are LFTs old hat?

Area of Science:

• Hepatology
• Biomarkers
• Medical Imaging

Background:

• End-stage liver disease presents a growing economic burden, driven by increased rates of cirrhosis from alcohol, viral hepatitis, and fatty liver disease.
• Early intervention can prevent many cases of cirrhosis, highlighting the need for effective screening methods.
• Current liver function tests (LFTs) often fail to detect significant liver fibrosis or cirrhosis, necessitating improved diagnostic approaches.

Purpose of the Study:

• To review the emerging roles of serum biomarkers and advanced imaging techniques in screening for liver disease.
• To evaluate the limitations of conventional liver function tests in detecting early or advanced liver conditions.

Main Methods:

• Literature review of recent studies on non-invasive screening modalities for liver disease.
• Analysis of the diagnostic performance of serum biomarkers and imaging techniques.
• Comparison of novel methods with traditional liver function tests.

Main Results:

• Liver function tests (LFTs) exhibit limited predictive value and can be normal in patients with significant liver fibrosis or cirrhosis.
• Emerging non-invasive serum biomarkers and imaging techniques show potential for improved early detection and screening of liver diseases.
• The relationships between LFTs and underlying liver conditions are often non-linear and unreliable for screening.

Conclusions:

• There is a critical need for advanced, non-invasive screening tools beyond LFTs to manage the rising prevalence of liver disease.
• Serum biomarkers and imaging techniques represent promising future directions for the early detection and management of liver conditions.
• Further research and validation are required to establish the clinical utility of these novel screening modalities.